57460-41-0

Basic information

• Product Name: Talinolol
• Synonyms: 1-(3-(3-Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol;1-(4-(Cyclohexylureido)phenoxy)-3-(tert-butylamino)-2-propanol;1-(4-Cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane;Cordanum;Racemic talinolol;rac-Talinolol ;1-(4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-3-cyclohexylurea;1-(4-(3-(tert-butylaMino)-2-hydroxypropoxy)phenyl)-3-cyclohexylu
• CAS NO: 57460-41-0
• Molecular Formula: C20H33N3O3
• Molecular Weight: 363.499
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 57460-41-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 160-162°C
• Boiling Point: 520 °C at 760 mmHg
• Flash Point: 268.3 °C
• Appearance: /
• Density: 1.11 g/cm³
• Vapor Pressure: 1.23E-11mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.82±0.20(Predicted)
• CAS DataBase Reference: Talinolol(CAS DataBase Reference)
• NIST Chemistry Reference: Talinolol(57460-41-0)
• EPA Substance Registry System: Talinolol(57460-41-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57460-41-0(Hazardous Substances Data)

Usage

Description

Talinolol, also known as (±)-Talinolol, is a β1-selective adrenoceptor antagonist that is structurally related to Practolol. It is recognized for its cardioprotective and antihypertensive activity. Talinolol works by blocking β1-adrenergic receptors, which results in the delay of conduction of stimuli in the AV node, reduction of the sino-atrial conduction time, and impairment of the sinus node automaticity. Its metabolism in human liver microsomes is well understood, making it a valuable tool for examining the activity of the drug-transporting MDR1 gene product P-glycoprotein. Talinolol is an off-white to pale pink solid.

Uses

Used in Pharmaceutical Industry:
Talinolol is used as an antihypertensive agent for the treatment of high blood pressure. It helps in reducing the heart rate and the force of heart contractions, thus lowering the blood pressure.
Used in Cardiology:
Talinolol is used as an antiarrhythmic agent for the management of abnormal heart rhythms. By blocking the β1-adrenergic receptors, it can help stabilize the heart's rhythm and prevent life-threatening arrhythmias.
Used in Drug Metabolism Research:
Talinolol is used as a research tool for studying the activity of the drug-transporting MDR1 gene product P-glycoprotein. Its well-understood metabolism in human liver microsomes makes it an ideal candidate for investigating the role of P-glycoprotein in drug transport and resistance.

references

[1] abmann i. the actions of talinolol, a β1-selective beta blocker, in cardiac arrhythmia and acute myocardial infarction[j]. current medical research and opinion, 2008, 13(6): 325-342.[2] trausch b, oertel r, richter k, et al. disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man[j]. biopharmaceutics & drug disposition, 1995, 16(5): 403-414.

InChI:InChI=1/C20H33N3O3/c1-20(2,3)21-13-17(24)14-26-18-11-9-16(10-12-18)23-19(25)22-15-7-5-4-6-8-15/h9-12,15,17,21,24H,4-8,13-14H2,1-3H3,(H2,22,23,25)

Upstream product

• 13080-65-4 2-methyl-N-(oxiran-2-ylmethyl)propan-2-amine 
• 38652-23-2 1-cyclohexyl-3-(4-hydroxyphenyl)urea 
• 51-78-5 p-aminophenol hydrochloride 
• 3173-53-3 Cyclohexyl isocyanate 

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Attempts to synthesize new β1 receptor blockers

-